Alzheimer's Disease | Progress In Mind

Home

Aiming for personalized treatment — detecting true-positive subgroups

The ultimate goal for personalized medicine is to prescribe the right treatment for the right...

Patient-reported outcomes — need for more guidance and consistency

Patient-reported outcomes (PROs) are increasingly important for regulators. However, the European...

Alzheimer's Disease

New insights into Apolipoprotein E and Alzheimer’s Disease

Apolipoprotein E4 is a major risk factor for Alzheimer’s Disease and is strongly related to...

Alzheimer's Disease

Talking about biomarker test results in Alzheimer’s disease

We still need to understand how disclosure of a positive biomarker test for Alzheimer’s...

Alzheimer's Disease

Advances in the early diagnosis of Alzheimer’s Disease

Many challenges exist in a patient’s journey to their diagnosis of Alzheimer’s Disease...

Alzheimer's Disease

Congress highlights

Encouraging immune response to AD: adjuvants, modifying the microbiome, and microglial rejuvenation

Modulating central and peripheral innate immunity has potential in Alzheimer’s Disease....

Alzheimer's Disease

Congress highlights

Making ready for early AD diagnosis

When disease-modifying therapy becomes available, screening for Alzheimer’s and its...

Alzheimer's Disease

Congress highlights

What have we learned from Alzheimer’s trials?

Recent phase 3 trials in Alzheimer’s Disease teach us how to improve selection of patients so...

Alzheimer's Disease

Vulnerability and resilience in Alzheimer’s Disease

Early life stress aggravates Alzheimer’s Disease (AD) pathology and early life enrichment...

Alzheimer's Disease

Could targeting the brain’s clearance systems be beneficial in Alzheimer’s Disease?

Amyloid-beta (Aβ) accumulation in Alzheimer’s Disease (AD) may, in part, be due to an...

Alzheimer's Disease

Taking a closer look at tau

Our understanding of tau pathology, a critical component of Alzheimer’s Disease development,...

Alzheimer's Disease

How beneficial is cholinesterase inhibition and for whom?

New evidence suggests that cholinesterase inhibition in prodromal Alzheimer’s disease (AD)...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind MENA Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind South East Asia Continue to Progress in Mind South Africa Continue to Progress in Mind United Kingdom Continue to Progress in Mind Sweden Continue to Progress in Mind Norge Continue to Progress in Mind Denmark Continue to Progress in Mind Finland Continue to Progress in Mind Japan

You are leaving Progress in Mind

Continue to

Cancel

You are leaving

Progress in Mind South East Asia
HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in South East Asia click here.

Already registered Register

Login as a registered health care professional

Please enter your email to continue

Register as a health care professional

Please enter your email to continue

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline